Reviva Pharmaceuticals announced positive results from its Phase 3 RECOVER open-label extension study evaluating brilaroxazine for treating schizophrenia. The study demonstrated robust and sustained ...

Brain drug developer MapLight Therapeutics lost two-thirds of its market value Monday after unveiling clinical trial results that, while positive, raised doubts about whether one of its experimental ...

Xanomeline-trospium (KarXT) — a novel therapy that combines a muscarinic receptor agonist with an anticholinergic agent — led to statistically significant and clinically meaningful improvements in ...

Detailed price information for Maplight Therapeutics Inc (MPLT-Q) from The Globe and Mail including charting and trades.

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics ®, a clinical-stage biopharmaceutical company, today announced positive data from the STARLYNG-1 (LYN-005-C-301) study, comparing the ...

CUPERTINO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that ...

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...

Schizophrenia, which is characterized by positive symptoms (e.g., hallucinations and delusions), negative symptoms (diminished emotional expressions or avolition), and cognitive impairments (attention ...

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and ...